Envista (NVST) Stock Forecast & Price Target

NVST Forecast - Frequently Asked Questions

What is Envista's forecast for 2026?

According to the research reports of 15 Wall Street equities research analysts, the average twelve-month stock price forecast for Envista is $28.25, with a high forecast of $35.00 and a low forecast of $21.00.

Should I buy or sell Envista stock right now?

15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Envista in the last year. There are currently 9 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" NVST shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVST, but not buy additional shares or sell existing shares.

Does Envista's stock price have much upside?

According to analysts, Envista's stock has a predicted upside of 7.88% based on their 12-month stock forecasts.

Has Envista been upgraded or downgraded by Wall Street analysts recently?

Over the previous 90 days, Envista's stock had 4 upgrades and 1 downgrade by analysts.

What analysts cover Envista?

Envista has been rated by research analysts at Barclays, Citigroup, Evercore, JPMorgan Chase & Co., Leerink Partners, Mizuho, Morgan Stanley, Piper Sandler, Robert W. Baird, Stifel Nicolaus, Weiss Ratings, Wells Fargo & Company, William Blair, and Zacks Research in the past 90 days.

Do Wall Street analysts like Envista more than its competitors?

Analysts like Envista more than other "medical" companies. The consensus rating score for Envista is 2.40 while the average consensus rating score for "medical" companies is 2.30. Learn more on how NVST compares to other companies.